Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo

Pharmacogenetics and Genomics

Volumn 24, Issue 2, 2014, Pages 118-128

  Piliguian, Mark ^a   Zhu, Andy Z X ^a   Zhou, Qian ^a   Benowitz, Neal L ^b   Ahluwalia, Jasjit S ^c   Sanderson Cox, Lisa ^d   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; CYP2A6; genetic variation; nicotine metabolism; smoking

Indexed keywords

COMPLEMENTARY DNA; COTININE; CYTOCHROME P450 2A6; CYTOCHROME P450 REDUCTASE; NICOTINE;

AFRICAN AMERICAN; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THERMOSTABILITY; TURNOVER TIME; WESTERN BLOTTING;

NICOTIANA TABACUM;

AFRICAN AMERICANS; ARYL HYDROCARBON HYDROXYLASES; ENZYME STABILITY; EVOLUTION, MOLECULAR; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; NICOTINE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84894985623     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000026     Document Type: Article

References (46)

1. Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362:2295-2303
2. CDC. Current cigarette smoking among adults -United States, 2011. Morb Mortal Wkly Rep 2012; 61:889-894
3. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24:1212-1217
4. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 2009; 85:635-643
5. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77:145-158
6. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14:615-626
7. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011; 103:1342-1346
8. Lerman C, Tyndale R, Patterson F, Wileyto E, Shields P, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79:600-608
9. Patterson F, Schnoll RA,Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: A randomized placebocontrolled trial of bupropion. Clin Pharmacol Ther 2008; 84:320-325
10. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393:750
11. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000; 6:4409-4415
12. Murai K, Yamazaki H, Nakagawa K, Kawai R, Kamataki T. Deactivation of anticancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 2009; 39:795-802
13. Di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19:300-309
14. Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 2011; 90:693-700
15. Fushiya N, Takagi I, Nishino H, Akizuki S, Ohnishi A. Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. Anticancer Drugs 2013; 24:617-622
16. Dempsey D, Tutka P, Jacob P III, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004; 76:64-72
17. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Characterization of CYP2A6 involved in 30-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996; 277:1010-1015
18. St Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P 3rd, Aziziyeh A, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev 2012; 21:1105-1114
19. Binnington MJ, Zhu AZ, Renner CC, Lanier AP, Hatsukami DK, Benowitz NL, et al. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska native people. Pharmacogenet Genomics 2012; 22:429-440
20. Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: Prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol 2006; 30:386-389
21. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 30-hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics 2009; 19:388-398
22. Pitarque M, von Richter O, Rodriguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 2004; 23:258-266
23. Gillam EM, Aguinaldo AM, Notley LM, Kim D, Mundkowski RG, Volkov AA, et al. Formation of indigo by recombinant mammalian cytochrome P450. Biochem Biophys Res Commun 1999; 265:469-472
24. Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF. A novel CYP2A6 allele, CYP2A6&z.ast;23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 2008; 18:67-75
25. Al Koudsi N, Ahluwalia JS, Lin S-K, Sellers EM, Tyndale RF. A novel CYP2A6 allele (CYP2A6&z.ast;35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J 2009; 9:274-282
26. Siu ECK,Wildenauer DB, Tyndale RF. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) 2006; 184:401-408
27. Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al. Bupropion for smoking cessation in African American light smokers: A randomized controlled trial. J Natl Cancer Inst 2012; 104:290-298
28. Zhu AZX, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. CYP2B6 and bupropion's smoking-cessation pharmacology: The role of hydroxybupropion. Clin Pharmacol Ther 2012; 92:771-777
29. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: Server and survey. Nucleic Acids Res 2002; 30:3894-3900
30. Bloom AJ, Harari O, Martinez M, Madden PA, Martin NG, Montgomery GW, et al. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. Hum Mol Genet 2012; 21:3050-3062
31. Bloom AJ, Harari O, Martinez M, Zhang X, McDonald SA, Murphy SE, et al. A compensatory effect upon splicing results in normal function of the CYP2A6&z.ast;14 allele. Pharmacogenet Genomics 2013; 23:107-116
32. Wang Y, Geer LY, Chappey C, Kans JA, Bryant SH. Cn3D: Sequence and structure views for Entrez. Trends Biochem Sci 2000; 25:300-302
33. Betts MJ, Russel RB. Amino acid properties and consequences of substitutions. In: Barnes MR, Gray IC, editors. Bioinformatics for geneticists. New York: Wiley; 2003. pp. 289-316
34. Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 2008; 29:679-688
35. Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, et al. A novel mutant allele of the CYP2A6 gene (CYP2A6&z.ast;11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12:299-306
36. Wang H, Bian T, Liu D, Jin T, Chen Y, Lin A, et al. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. Pharmacogenomics 2011; 12:481-492
37. Tanii H, Shitara Y, Horie T. Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. Eur J Clin Pharmacol 2011; 67:1017-1025
38. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c.516G->T) and CYP2A6 (&z.ast;9B and/or &z.ast;17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009; 67:427-436
39. Rossini A, de Almeida Simao T, Albano RM, Pinto LF. CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics 2008; 9:1737-1752
40. Zhu AZ, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, Stepanov I, et al. Alaska native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis 2013; 34:93-101
41. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354:333-342
42. Pinsky PF. Racial and ethnic differences in lung cancer incidence: How much is explained by differences in smoking patterns? (United States). Cancer Causes Control 2006; 17:1017-1024
43. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461:747-753
44. Marth GT, Yu F, Indap AR, Garimella K, Gravel S, Leong WF, et al. The functional spectrum of low-frequency coding variation. Genome Biol 2011; 12:R84
45. Maxmen A. Exome sequencing deciphers rare diseases. Cell 2011; 144:635-637
46. Raychaudhuri S. Mapping rare and common causal alleles for complex human diseases. Cell 2011; 147:57-69